Outcome (studies)
Improvement
Relative risk · 95% CI
00.511.5+
← Belnacasan
reduces riskIncreased
risk →
reduces riskIncreased
risk →
Belnacasan for COVID-19
1
study with
31
patients
No significant improvements are seen in meta-analysis to date.
COVID-19 Belnacasan studies · November 2026
|
Outcome (studies)
Improvement
Relative risk · 95% CI
00.511.5+
← Belnacasan
reduces riskIncreased risk → |
Oct 11 2022 |
et al., NCT05164120 | A Proof of Concept, Randomized, Double-blind, Placebo-controlled Trial of Orally Administered Belnacasan Tablets for the Treatment of Mild to Moderate COVID-19 |
| 34% slower recovery (p=0.29). RCT 40 outpatients in the USA, showing no significant difference in recovery with belnacasan treatment. | ||
